Skip to content
sellWeak cluster of 210b5-1 plan

Dominic Piscitelli sold $160k of ORIC

Chief Financial Officer at Oric Pharmaceuticals, Inc.. 11,000 shares at an average of $14.52, traded Oct 6, 2025, filed Oct 8, 2025.

Warning score
11
Value
$160k
11,000 shares
Holdings after
48,317
-19% from before
From 52-week low
+239%
low $4.26, close $14.41
From 52-week high
0%
high $14.41, as of Oct 6, 2025

Score components

  • Role
    CFO
    +22
  • Trade size
    $160k at market
    +11
  • Share of holdings sold
    Sold 19% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ORICOct 9, 2026 · close 11.99
Since filing Oct 8, 2025: -16.0%SPY +16.9% · excess -33.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001695028-25-000004, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 6, 2025MOption exercise
Common Stock10b5-1
+11,000$4.36$48k59,317Oct 8, 2025
Oct 6, 2025SOpen-market sale
Common Stock10b5-1
-11,000$14.52$160k48,317Oct 8, 2025
Oct 6, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-11,000$0.00$0196,500Oct 8, 2025

Related signals

Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
2Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Richard A. Heyman
director
$87k
6,700 shares
-16%
12Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$181k
13,400 shares
-16%
0Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$8,103
600 shares
-1%
39Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$302k
33,374 shares
-5%
30Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Pratik S Multani
Chief Medical Officer
$97k
10,720 shares
-14%
37Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$97k
10,720 shares
-14%
30Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$462k
37,461 shares
-7%
43Moderate
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$1.1M
87,539 shares
-13%
43Moderate
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$1.3M
125,000 shares
-16%
24Weak
ORICsell10b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$201k
20,000 shares
-29%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Dominic Piscitelli sold $160k of ORIC | InsiderTell